JP2023516957A - ダプトマイシン製剤 - Google Patents
ダプトマイシン製剤 Download PDFInfo
- Publication number
- JP2023516957A JP2023516957A JP2022551653A JP2022551653A JP2023516957A JP 2023516957 A JP2023516957 A JP 2023516957A JP 2022551653 A JP2022551653 A JP 2022551653A JP 2022551653 A JP2022551653 A JP 2022551653A JP 2023516957 A JP2023516957 A JP 2023516957A
- Authority
- JP
- Japan
- Prior art keywords
- daptomycin
- formulation
- solid
- reconstitution time
- dosage form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025120933A JP2025142200A (ja) | 2020-02-28 | 2025-07-18 | ダプトマイシン製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062982945P | 2020-02-28 | 2020-02-28 | |
| US62/982,945 | 2020-02-28 | ||
| PCT/EP2021/054841 WO2021170807A1 (en) | 2020-02-28 | 2021-02-26 | Daptomycin formulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025120933A Division JP2025142200A (ja) | 2020-02-28 | 2025-07-18 | ダプトマイシン製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023516957A true JP2023516957A (ja) | 2023-04-21 |
| JP2023516957A5 JP2023516957A5 (enExample) | 2023-12-07 |
Family
ID=74797935
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022551653A Pending JP2023516957A (ja) | 2020-02-28 | 2021-02-26 | ダプトマイシン製剤 |
| JP2025120933A Pending JP2025142200A (ja) | 2020-02-28 | 2025-07-18 | ダプトマイシン製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025120933A Pending JP2025142200A (ja) | 2020-02-28 | 2025-07-18 | ダプトマイシン製剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230068866A1 (enExample) |
| EP (1) | EP4110303A1 (enExample) |
| JP (2) | JP2023516957A (enExample) |
| CN (2) | CN118873500A (enExample) |
| AU (1) | AU2021227095B2 (enExample) |
| BR (1) | BR112022015571A2 (enExample) |
| CA (1) | CA3168727A1 (enExample) |
| MX (1) | MX2022010378A (enExample) |
| WO (1) | WO2021170807A1 (enExample) |
| ZA (1) | ZA202208343B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2770366C2 (ru) | 2017-08-31 | 2022-04-15 | Кселлия Фармасьютикалз Апс | Препараты даптомицина |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003055256A (ja) * | 2001-08-10 | 2003-02-26 | Nihon Pharmaceutical Co Ltd | 安定な血液凝固第xiii因子製剤 |
| WO2019043008A1 (en) * | 2017-08-31 | 2019-03-07 | Xellia Pharmaceuticals Aps | DAPTOMYCIN FORMULATIONS |
| WO2019096776A1 (en) * | 2017-11-15 | 2019-05-23 | Ucb Biopharma Sprl | Method for reducing the reconstitution time of spray-dried protein formulations |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2607526C2 (ru) | 2009-11-23 | 2017-01-10 | Кьюбист Фармасьютикалз ЭлЭлСи | Липопептидные композиции и родственные способы |
-
2021
- 2021-02-26 EP EP21708627.1A patent/EP4110303A1/en active Pending
- 2021-02-26 BR BR112022015571A patent/BR112022015571A2/pt unknown
- 2021-02-26 AU AU2021227095A patent/AU2021227095B2/en active Active
- 2021-02-26 US US17/794,734 patent/US20230068866A1/en active Pending
- 2021-02-26 CA CA3168727A patent/CA3168727A1/en active Pending
- 2021-02-26 CN CN202410944805.5A patent/CN118873500A/zh active Pending
- 2021-02-26 CN CN202180011662.7A patent/CN115038431B/zh active Active
- 2021-02-26 JP JP2022551653A patent/JP2023516957A/ja active Pending
- 2021-02-26 WO PCT/EP2021/054841 patent/WO2021170807A1/en not_active Ceased
- 2021-02-26 MX MX2022010378A patent/MX2022010378A/es unknown
-
2022
- 2022-07-26 ZA ZA2022/08343A patent/ZA202208343B/en unknown
-
2025
- 2025-07-18 JP JP2025120933A patent/JP2025142200A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003055256A (ja) * | 2001-08-10 | 2003-02-26 | Nihon Pharmaceutical Co Ltd | 安定な血液凝固第xiii因子製剤 |
| WO2019043008A1 (en) * | 2017-08-31 | 2019-03-07 | Xellia Pharmaceuticals Aps | DAPTOMYCIN FORMULATIONS |
| WO2019096776A1 (en) * | 2017-11-15 | 2019-05-23 | Ucb Biopharma Sprl | Method for reducing the reconstitution time of spray-dried protein formulations |
Also Published As
| Publication number | Publication date |
|---|---|
| CN118873500A (zh) | 2024-11-01 |
| US20230068866A1 (en) | 2023-03-02 |
| ZA202208343B (en) | 2024-11-27 |
| CA3168727A1 (en) | 2021-09-02 |
| BR112022015571A2 (pt) | 2022-09-27 |
| MX2022010378A (es) | 2022-09-21 |
| AU2021227095B2 (en) | 2024-02-22 |
| AU2021227095A1 (en) | 2022-08-25 |
| JP2025142200A (ja) | 2025-09-30 |
| CN115038431B (zh) | 2024-08-09 |
| CN115038431A (zh) | 2022-09-09 |
| WO2021170807A1 (en) | 2021-09-02 |
| EP4110303A1 (en) | 2023-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7229999B2 (ja) | ダプトマイシン製剤 | |
| JP4077794B2 (ja) | 抗新生物薬剤、特にテモゾロミドの薬学的処方物、その同一物の製造方法および使用方法 | |
| JP6041673B2 (ja) | リポペプチド組成物および関連する方法 | |
| JP2023018090A (ja) | 高濃度のタンパク質ベース治療薬を含有する医薬組成物における安定化化合物としてのアミノ酸の使用 | |
| EP2219605B1 (en) | Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents | |
| JP2012167132A (ja) | N−[o−(p−ピバロイルオキシベンゼンスルホニルアミノ)ベンゾイル]グリシン・モノナトリウム塩・4水和物の凍結乾燥製剤 | |
| AU2007321977A1 (en) | Stable parenteral formulation containing a RSV inhibitor of a benzodiazepine structure | |
| CN115990138A (zh) | 包含高纯度坎格雷洛的药物制剂以及制备和使用它们的方法 | |
| JP2025142200A (ja) | ダプトマイシン製剤 | |
| ES2342833T3 (es) | Formulacion liofilizada estabilizada, para derivados de cefalosporina. | |
| AU2006329849A1 (en) | Lyophilized compositions of a triazolopyrimidine compound | |
| WO2017085696A1 (en) | Parenteral formulations of melphalan | |
| AU2018328532A1 (en) | Pharmaceutical composition of docetaxel conjugate and preparation method | |
| JP4880845B2 (ja) | Grf含有凍結乾燥薬剤組成物 | |
| AU2016364380B2 (en) | Formulations for intravenous injection of danirixin | |
| EP2968595A2 (en) | Voriconazole formulations | |
| WO2023209731A1 (en) | Injectable liquid or lyophilized powder dosage forms of selexipag and their method of preparation | |
| JP2023510258A5 (enExample) | ||
| CN101669916A (zh) | 一种硝苯地平冻干粉针的制备方法 | |
| WO2005123137A2 (en) | Lyophilized pharmaceutical composition comprising moxifloxacin hydrochloride | |
| HK1111344A (en) | Stabilized freeze-dried formulation for cephalosporin derivatives | |
| TW201302755A (zh) | 含胺基酸穩定劑的替莫唑胺醫藥組成物及其製備方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231129 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20231129 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20241015 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20241016 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250110 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20250430 |